Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03031691 | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | PHASE1 | COMPLETED | 7 | — | — | Jan 1, 2017 | Sep 1, 2017 | Aug 11, 2020 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Brontictuzumab and trifluridine/tipiracil | EXPERIMENTAL | Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label. |
| Name | Type | Description |
|---|---|---|
| brontictuzumab | DRUG | starting dose of 1.5mg/kg administered intravenously (IV) |
| trifluridine/tipiracil | DRUG | - |
Inclusion Criteria: * Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if KRAS wild-type, an anti-EGFR therapy * ECOG performance status 0 or 1 Exclusion Crit...